PMID- 23998254
OWN - NLM
STAT- MEDLINE
DCOM- 20150715
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 6
DP  - 2014 Jun
TI  - A systematic review of comparative schedule-related toxicities with maintenance 
      rituximab in follicular and mantle cell lymphomas.
PG  - 1288-94
LID - 10.3109/10428194.2013.839787 [doi]
AB  - Abstract We conducted a systematic review of grade 3/4 adverse events (AEs) 
      reported in prospective trials enrolling patients with follicular lymphoma (FL) 
      and mantle cell lymphoma (MCL) receiving maintenance rituximab (MR). 
      Random-effects models were used to calculate summary estimates and 95% confidence 
      intervals for the proportion of AEs occurring during MR. Differences by induction 
      program, histology, setting and MR schedule were examined by stratified analyses 
      and univariate random-effects meta-regression. Eleven trials met the search 
      criteria, with nine sufficiently reporting AEs during the MR phase. Of 1009 
      patients receiving MR, the proportion experiencing cumulative grade 3/4 toxicity 
      was 24% (95% confidence interval [CI]: 14-36%). Patients receiving MR every 6 
      months as four weekly infusions for 2 years had significantly less toxicity 
      compared with those receiving MR every 2 months (10% vs. 28%; p = 0.035). 
      Patients treated with rituximab alone during induction had fewer toxicities 
      compared to those treated with rituximab plus chemotherapy induction (12% vs. 
      35%; p = 0.031). Myelosuppression and infections were the most common toxicities. 
      Our literature analysis suggests that MR given every 6 months and rituximab alone 
      as induction may be associated with fewer grade 3/4 AEs for patients with FL and 
      MCL; however, assessing the true independent impact of induction regimens and 
      schedule on toxicity will require prospective trials.
FAU - Nabhan, Chadi
AU  - Nabhan C
AD  - Section of Hematology and Oncology, Department of Medicine.
FAU - Ollberding, Nicholas J
AU  - Ollberding NJ
FAU - Villines, Dana
AU  - Villines D
FAU - Chiu, Brian C-H
AU  - Chiu BC
FAU - Caces, Donne Bennett D
AU  - Caces DB
FAU - Valdez, Tina V
AU  - Valdez TV
FAU - Ghielmini, Michele
AU  - Ghielmini M
FAU - Hsu Schmitz, Shu-Fang
AU  - Hsu Schmitz SF
FAU - Smith, Sonali M
AU  - Smith SM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20131101
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Antineoplastic Agents/administration & dosage/*adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Humans
MH  - Lymphoma, Follicular/*drug therapy
MH  - Lymphoma, Mantle-Cell/*drug therapy
MH  - Maintenance Chemotherapy
MH  - Rituximab
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Rituximab
OT  - follicular lymphoma
OT  - lymphoma
OT  - maintenance rituximab
OT  - mantle cell lymphoma
EDAT- 2013/09/04 06:00
MHDA- 2015/07/16 06:00
CRDT- 2013/09/04 06:00
PHST- 2013/09/04 06:00 [entrez]
PHST- 2013/09/04 06:00 [pubmed]
PHST- 2015/07/16 06:00 [medline]
AID - 10.3109/10428194.2013.839787 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Jun;55(6):1288-94. doi: 10.3109/10428194.2013.839787. Epub 
      2013 Nov 1.